T26A

T26A (5 μM; 10 min) inhibits 94% of PGT-mediated [³H]PGE₂ uptake in PGT-MDCK cells^[1].
T26A (500-1000 nM; 2 min) acts as a competitive inhibitor of PGT in PGT-MDCK cells, with a K_i of 378 nM^[1].
T26A (0.5-50 μM) exerts no significant effect on the activity of purified ovine COX1, ovine COX2 or human recombinant COX2 enzymes; it also shows no significant effect on the activity of purified human recombinant m-PGES enzyme^[1].
T26A (5 μM) has no effect on the synthesis and release of PGE₂ in WT-MDCK cells treated with 1 μM arachidonic acid (HY-109590) for different durations^[1].
T26A (5 μM; 10-180 min) blocks PGT-mediated influx and metabolism of endogenous PGE₂ in PGT-MDCK cells, maintains extracellular PGE₂ at the level observed in WT-MDCK cells, and reduces the levels of intracellular PGE₂ metabolites^[1].
T26A (5 μM; 10-180 min) abolishes PGT-mediated metabolism of exogenous 10 nM PGE₂ in PGT-MDCK cells, allowing extracellular PGE₂ to persist and reducing intracellular PGE₂ metabolites^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.